THERAPEUTIC OR PROPHYLACTIC AGENT FOR DYSKINESIA
    1.
    发明申请
    THERAPEUTIC OR PROPHYLACTIC AGENT FOR DYSKINESIA 有权
    DYSKINESIA的治疗剂或预防剂

    公开(公告)号:US20120058186A1

    公开(公告)日:2012-03-08

    申请号:US13257820

    申请日:2010-03-29

    摘要: The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer.

    摘要翻译: 本发明涉及一种含有药物的稳定的口腔崩解型包衣片剂,其中片剂的涂层含有不少于5重量%的水溶性物质和聚乙烯醇树脂,基于涂层的重量 层,在20℃下在少于10mL的水中溶解1g或更多的水溶性物质,其分子中具有羟基,分子量不大于200 每单位羟基。 提供了一种稳定的口腔崩解性包衣片剂,即使在口腔崩解片剂在高湿度下通过吸湿而膨胀,同时确保口腔中快速崩解性能,也不会在包衣层中引起裂纹。 在含有光不稳定药物的口腔崩解片剂的情况下,可以通过在遮光层中混合遮光剂来抑制药物的降解。

    Therapeutic or prophylactic agent for dyskinesia
    2.
    发明授权
    Therapeutic or prophylactic agent for dyskinesia 有权
    运动障碍的治疗或预防剂

    公开(公告)号:US08715730B2

    公开(公告)日:2014-05-06

    申请号:US13257820

    申请日:2010-03-29

    IPC分类号: A61K9/32

    摘要: The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer.

    摘要翻译: 本发明涉及一种含有药物的稳定的口腔崩解型包衣片剂,其中片剂的涂层含有不少于5重量%的水溶性物质和聚乙烯醇树脂,基于涂层的重量 层,在20℃下在少于10mL的水中溶解1g或更多的水溶性物质,其分子中具有羟基,分子量不大于200 每单位羟基。 提供了一种稳定的口腔崩解性包衣片剂,即使在口腔崩解片剂在高湿度下通过吸湿而膨胀,同时确保口腔中快速崩解性能,也不会在包衣层中引起裂纹。 在含有光不稳定药物的口腔崩解片剂的情况下,可以通过在遮光层中混合遮光剂来抑制药物的降解。

    Stable tablet containing 4,5-epoxymorphinan derivative
    3.
    发明授权
    Stable tablet containing 4,5-epoxymorphinan derivative 有权
    含有4,5-环氧吗啡喃衍生物的稳定片剂

    公开(公告)号:US08829019B2

    公开(公告)日:2014-09-09

    申请号:US13125726

    申请日:2009-10-23

    摘要: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.

    摘要翻译: 本发明涉及包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分的稳定片剂。 也就是说,根据本发明的片剂包括:(1)作为有效成分的特定的4,5-环氧吗啡喃衍生物或药理学上可接受的酸加成盐; (2)硫代硫酸钠; (3)选自糖和糖醇的至少一种; 和(4)交聚维酮,羧甲基淀粉钠或其混合物,其中上述(4)的含量为含有上述有效成分的每单位重量的1至20重量%。

    Stable solid preparation containing 4,5-epoxymorphinan derivative
    4.
    发明授权
    Stable solid preparation containing 4,5-epoxymorphinan derivative 有权
    稳定的固体制剂含有4,5-环氧基吗啡喃衍生物

    公开(公告)号:US08420662B2

    公开(公告)日:2013-04-16

    申请号:US12597475

    申请日:2008-04-25

    摘要: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient.That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.

    摘要翻译: 本发明的目的是提供一种稳定的固体制剂,其包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分。 也就是说,本发明提供了包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分的稳定的固体制剂,并且包含硫代硫酸钠,糖或糖醇和羟丙基纤维素 以含有有效成分的单位重量计1〜30重量%的量的替代。

    STABLE TABLET CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE
    5.
    发明申请
    STABLE TABLET CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE 有权
    包含4,5-EPOXYMORPHANAN衍生物的稳定片剂

    公开(公告)号:US20120114752A1

    公开(公告)日:2012-05-10

    申请号:US13125726

    申请日:2009-10-23

    IPC分类号: A61K31/485 A61P17/04 A61K9/28

    摘要: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.

    摘要翻译: 本发明涉及包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分的稳定片剂。 也就是说,根据本发明的片剂包括:(1)作为有效成分的特定的4,5-环氧吗啡喃衍生物或药理学上可接受的酸加成盐; (2)硫代硫酸钠; (3)选自糖和糖醇的至少一种; 和(4)交聚维酮,羧甲基淀粉钠或其混合物,其中上述(4)的含量为含有上述有效成分的每单位重量的1至20重量%。

    STABLE SOLID PREPARATION CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE
    6.
    发明申请
    STABLE SOLID PREPARATION CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE 有权
    含有4,5-EPOXYMORPHINAN衍生物的稳定的固体制剂

    公开(公告)号:US20100120815A1

    公开(公告)日:2010-05-13

    申请号:US12597475

    申请日:2008-04-25

    IPC分类号: A61K31/485 A61P17/04

    摘要: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient.That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.

    摘要翻译: 本发明的目的是提供一种稳定的固体制剂,其包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分。 也就是说,本发明提供了包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分的稳定的固体制剂,并且包含硫代硫酸钠,糖或糖醇和羟丙基纤维素 以含有有效成分的单位重量计1〜30重量%的量的替代。

    Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
    7.
    发明授权
    Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation 有权
    药物固体制剂用涂料,药物膜制剂和涂层药物固体制剂

    公开(公告)号:US09381248B2

    公开(公告)日:2016-07-05

    申请号:US13819523

    申请日:2011-08-31

    IPC分类号: A61K47/10 A61K9/28 A61K47/02

    摘要: A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.

    摘要翻译: 用于药物固体制剂的包衣剂赋予具有与PTP片剂相当的优异阻隔性能的未包装的药物固体制剂,而不影响药物固体制剂的崩解性能。 用于药物固体制剂的涂布剂包括平均分子量为950至25,000的聚乙二醇和溶胀性粘土,其中聚乙二醇和溶胀粘土的质量比为2:8至6:4。

    COATING AGENT FOR PHARMACEUTICAL SOLID PREPARATION, PHARMACEUTICAL FILM FORMULATION, AND COATED PHARMACEUTICAL SOLID PREPARATION
    8.
    发明申请
    COATING AGENT FOR PHARMACEUTICAL SOLID PREPARATION, PHARMACEUTICAL FILM FORMULATION, AND COATED PHARMACEUTICAL SOLID PREPARATION 有权
    药物固体制剂涂料,药物膜制剂和涂层药物固体制剂

    公开(公告)号:US20130156829A1

    公开(公告)日:2013-06-20

    申请号:US13819523

    申请日:2011-08-31

    IPC分类号: A61K47/10 A61K47/02

    摘要: A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.

    摘要翻译: 用于药物固体制剂的包衣剂赋予具有与PTP片剂相当的优异阻隔性能的未包装的药物固体制剂,而不影响药物固体制剂的崩解性能。 用于药物固体制剂的涂布剂包括平均分子量为950至25,000的聚乙二醇和溶胀性粘土,其中聚乙二醇和溶胀粘土的质量比为2:8至6:4。